Virginia Commonwealth University
Defining a Simplified Pharmacophore for Simocyclinone D8 Inhibition of DNA Gyrase
Abstract
dc:description.abstractThe type II topoisomerase subfamily of enzymes has been clinically targeted by the widely used, broad-spectrum quinolone class of antibacterials. Due to emerging drug-resistant strains of bacteria, the quinolones’ effectiveness is threatened. The natural product simocyclinone D8 (SD8) has shown the ability to inhibit the type II topoisomerase, DNA gyrase, even when mutated to be resistant to the quinolones. In order to determine the pharmacophore required for SD8 binding to DNA gyrase, 16 compounds were synthesized. These compounds were then tested by surface plasmon resonance for their ability to inhibit the DNA – DNA gyrase binding interaction. It was found that three compounds were able to inhibit the DNA – DNA gyrase binding interaction, while another showed partial inhibition of the interaction. From this data, a minimum pharmacophore was able to be determined. The pharmacophore required a coumarin scaffold bonded to a carboxylic acid group through an approximately 15 Å hydrocarbon linker. Functional supercoiling assays determined that while the compounds were able to bind the enzyme, the binding did not inhibit DNA gyrase’s ability to supercoil DNA.
Degree
thesis:*- Name thesis:degree_name
- Master of Pharmaceutical Sciences
- Level thesis:degree_level
- Thesis
- Discipline thesis:degree_discipline
- Pharmaceutical Sciences
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Gaskell, Lauren
- Contributors dc:contributor
-
- Keith Ellis
Subjects
dc:subject × 4Rights
dc:rights- Statement dc:rights
-
- © The Author
Identifiers
dc:identifier.*- Identifier
- https://scholarscompass.vcu.edu/etd/2949